<DOC>
	<DOCNO>NCT02662608</DOCNO>
	<brief_summary>The goal study start treatment NOTCH1 inhibitor brontictuzumab attempt control tumor prolong survival . The therapy involve participant give drug brontictuzumab treat adenoid cystic carcinoma ( ACC ) NOTCH 1 mutation . This consider investigational treatment .</brief_summary>
	<brief_title>Compassionate Use Brontictuzumab Adenoid Cystic Carcinoma ( ACC )</brief_title>
	<detailed_description>Treatment : Participant receive brontictuzumab vein 30 minute one time every 3 week . Clinic Visits : On Day 1 Cycle 1 every 3 week : - Participant physical exam - Blood ( 3 teaspoon ) draw routine test . Every 6 week , participant MRI CT scan check status disease . Length Treatment : Participant may continue take brontictuzumab long doctor think best interest . Participant longer able take drug disease get bad , develop another illness prevent receive treatment , intolerable side effect occur . Brontictuzumab FDA approve commercially available . It currently use research purpose .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Adenoid Cystic</mesh_term>
	<criteria>1 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 2 . Organ marrow function follow : absolute neutrophil count ( ANC ) ≥1000/mm3 , platelet ≥50,000/dL , hemoglobin ≥8 g/dL , bilirubin ≤ 1.5 time upper limit normal , serum creatinine ≤1.5 mg/dL creatinine clearance ≥50 mL/min , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 3 time upper limit normal . 3 . Central Nervous System ( CNS ) metastases allow subject require steroid , brain metastasis clinically stable without symptomatic progression 4 . Capability understand comply protocol sign informed consent document . 1 . Major medical condition might affect study participation ( e.g . uncontrolled pulmonary , renal , hepatic dysfunction , uncontrolled infection , cardiac disease ) 2 . Inability unwillingness abide study protocol cooperate fully investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Brontictuzumab</keyword>
</DOC>